Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study
about
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study
description
scientific article published on 22 February 2020
@en
name
Simeprevir, daclatasvir, and s ...... n-label, Phase II IMPACT study
@en
type
label
Simeprevir, daclatasvir, and s ...... n-label, Phase II IMPACT study
@en
prefLabel
Simeprevir, daclatasvir, and s ...... n-label, Phase II IMPACT study
@en
P2093
P50
P356
P1476
Simeprevir, daclatasvir, and s ...... n-label, Phase II IMPACT study
@en
P2093
Ann Vandevoorde
Donghan Luo
Fred Poordad
Greet Beets
Julio A Gutierrez
Maria Beumont
Mohamed Gamil
Pieter Van Remoortere
P356
10.1002/HSR2.145
P577
2020-02-22T00:00:00Z